Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.
Patient age ≥ 18 years. [+15]
Patient has another concurrent active invasive malignancy. [+13]